Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLitigation Cap. Regulatory News (LIT)

Share Price Information for Litigation Cap. (LIT)

Share Price is delayed by 15 minutes
Get Live Data
2.70    0.00 (0.00%)
Bid:
2.50
Ask:
2.70
Spread: 0.20 (8.00%)
Market Cap: £2.78m
LIT Live PriceLast checked at - London Stock Exchange

Intraday Litigation Cap. Share Chart

Transaction in Own Shares

16 Apr 2024 07:00

RNS Number : 7171K
Litigation Capital Management Ltd
16 April 2024
 

16 April 2024

Litigation Capital Management Limited

("LIT", the "Company" or the "Group")

Transaction in Own Shares

 

The Company announces that Canaccord Genuity Limited ("Canaccord") has made the following purchases of ordinary shares of no par value in the capital of the Company ("Ordinary Shares"), on its behalf on the London Stock Exchange, pursuant to the Share Buyback Programme announced on 5 October 2023.

Date of purchase

15 April 2024

Number of Ordinary Shares purchased (aggregated volume):

15,000

Highest Price paid per Ordinary Share (p):

109.00

Lowest Price paid per Ordinary Share (p):

109.00

Volume Weighted Average Price paid per Ordinary Share (p):

109.00

Venue where Ordinary Shares are traded

London Stock Exchange (AIM)

Canaccord holds the repurchased shares on behalf of the Company. Following the purchase, the number of Ordinary Shares in issue and admitted to trading on AIM will be 116,994,959 excluding shares held by Canaccord (being the "Total Share Capital"). Canaccord on behalf of the Company will hold 2,205,373 ordinary shares, representing approximately 1.885% per cent of the Total Share Capital.

 

This figure of 116,994,959 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

 

The Company and Canaccord will make further announcements in due course following the completion of any further purchases pursuant to the Share Buyback Programme.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation), the schedule below contains detailed information about the purchases made by Canaccord on behalf of the Company.

Individual transactions:

Number of shares purchased

Transaction price (pence per share)

Time of transaction

Trading venue

1,332

109.00

08:11:36

London Stock Exchange

1,823

109.00

08:11:36

London Stock Exchange

3,971

109.00

08:11:36

London Stock Exchange

1,431

109.00

08:11:36

London Stock Exchange

3,340

109.00

08:11:36

London Stock Exchange

3,103

109.00

09:50:35

London Stock Exchange

 

Enquiries

 

Litigation Capital Management

c/o Tavistock

Patrick Moloney, Chief Executive Officer

Mary Gangemi, Chief Financial Officer

 

 

Canaccord (Nomad and Joint Broker) 

Tel: 020 7523 8000

Bobbie Hilliam / Alex Orr

Investec Bank plc (Joint Broker)

Tel: 020 7597 5970

David Anderson

 

Tavistock (PR and IR)

Tel: 020 7920 3150

Tim Pearson

Katie Hopkins

lcm@tavistock.co.uk

 

NOTES TO EDITORS

Litigation Capital Management (LCM) is an alternative asset manager specialising in disputes financing solutions internationally, which operates two business models. The first is direct investments made from LCM's permanent balance sheet capital and the second is third party fund management. Under those two business models, LCM currently pursues three investment strategies: Single-case funding, Portfolio funding and Acquisitions of claims. LCM generates its income from both its direct investments and also performance fees through asset management.

 

LCM has an unparalleled track record driven by disciplined project selection and robust risk management. Currently headquartered in Sydney, with offices in London, Singapore, Brisbane and Melbourne, LCM listed on AIM in December 2018, trading under the ticker LIT.

 

www.lcmfinance.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
POSLELLFZZLXBBF
Date   Source Headline
1st Jun 20267:00 amRNSUpdate on Covenant Waiver, Case & Strategic Review
15th Apr 20267:30 amRNSCovenant Waiver Extension
31st Mar 20267:00 amRNSInterim results for the HY ended 31 December 2025
25th Mar 20267:00 amRNSNotice of H1 Results, Trading update and IMC
17th Mar 20267:00 amRNSJudgment Delivered in Commercial Litigation Claim
17th Mar 20267:00 amRNSJudgment Delivered in Commercial Litigation Claim
11th Mar 20269:34 amRNSUpdate on Case Investment and Strategic Review
2nd Mar 20267:00 amRNSCovenant Waiver Extension
2nd Feb 20267:00 amRNSIncrease in Credit Facility and Waiver Extension
12th Jan 20262:07 pmRNSPositive development on case
30th Dec 20257:00 amRNSCovenant Waiver Extension
30th Dec 20257:00 amRNSCovenant Waiver Extension
24th Dec 20257:00 amRNSAdverse Costs Order in Class Action Investment
27th Nov 20251:08 pmRNSResults of AGM
26th Nov 20255:00 pmRNSStrategic Review Update
19th Nov 202511:54 amRNSPosting of Annual Report and Accounts
4th Nov 20252:29 pmRNSNotice of Annual General Meeting
21st Oct 202511:37 amRNSPostponement of Annual General Meeting
13th Oct 202511:39 amRNSExercise of Awards
6th Oct 20257:00 amRNSUpdate on Commercial Arbitration Loss
2nd Oct 20258:40 amRNSTR-1
1st Oct 20254:49 pmRNSNotice of Annual General Meeting
1st Oct 202511:25 amRNSJudgment Delivered in Commercial Litigation Claim
1st Oct 20257:00 amRNSAnnual Results for the year ended 30 June 2025
15th Sep 20257:00 amRNSClass Action Investment and Strategic Review
8th Sep 20257:00 amRNSNotice of Results
23rd Jun 20259:45 amRNSTR - 1
19th Jun 20257:00 amRNSJudgment in Funded Case and Trading Update
13th May 20252:50 pmRNSStatement Regarding Media Speculation
1st Apr 20257:00 amRNSOutcome of Commercial Arbitration Investment
18th Mar 20257:00 amRNSInterim results for the HY ended 31 December 2024
7th Mar 20252:54 pmRNS-RInvestor Presentation via Investor Meet Company
28th Feb 20257:00 amRNSAppeal Filed in Class Action Investment
21st Feb 20257:00 amRNSJudgment Delivered in Class Action Investment
4th Feb 20258:33 amRNSHolding(s) in Company
29th Jan 20257:00 amRNSTrading Update
15th Jan 202511:14 amRNSHolding(s) in Company
19th Dec 20247:00 amRNSDirectorate Change
6th Dec 202411:15 amRNSHolding(s) in Company
6th Dec 20247:00 amRNSAppointment of CFO to the Board of Directors
4th Dec 20247:00 amRNSJudgment Delivered in Class Action Investment
2nd Dec 20247:00 amRNSNew Credit Facility
15th Nov 20247:00 amRNSDirector/PDMR Shareholding
8th Nov 20247:06 amRNSHolding(s) in Company
8th Nov 20247:00 amRNSTransaction in Own Shares
7th Nov 20247:00 amRNSTransaction in Own Shares
6th Nov 20247:00 amRNSTransaction in Own Shares
5th Nov 20247:00 amRNSTransaction in Own Shares
4th Nov 20247:00 amRNSTransaction in Own Shares
1st Nov 20247:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.